This is a preprint.
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder
- PMID: 38746408
- PMCID: PMC11092808
- DOI: 10.21203/rs.3.rs-4331201/v1
Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder
Abstract
Background: Medications for opioid use disorder (MOUD) are among the best tools we have to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low. Interventions to increase MOUD access in the United States have largely focused on improving organizational capacity and addressing funding barriers, yet stigma toward MOUD may inhibit uptake even where MOUD is readily available. Substance use disorder (SUD) treatment counselors likely have considerable influence on a client's choice to initiate and adhere to MOUD, but beliefs that counselors convey about MOUD in interaction with clients are understudied. The current study explores what advantages and disadvantages that SUD treatment counselors communicate about buprenorphine, methadone, and naltrexone.
Methods: From June to December 2021, we surveyed counselors from publicly-funded SUD treatment agencies under a municipality-wide mandate to offer MOUD to all clients with OUD. Counselors were asked to describe, in a free-response format, the most important advantages and disadvantages to communicate to their clients about taking buprenorphine, methadone, and naltrexone. Counselor responses were coded for one or more advantage and disadvantage.
Results: A total of 271 SUD counselors from 29 agencies completed the survey, generating 1,995 advantages and disadvantages across three types of MOUD. The most frequently reported advantage across all three types of MOUD was their ability to reduce cravings and illicit drug use. The most frequently reported disadvantage related to the potential for some types of MOUD to develop long-term medication dependence.
Conclusions: As the availability and variety of MOUD treatment options continue to expand, it is important that SUD counselors are equipped with evidence-based recommendations for OUD care. We identified misalignments with the MOUD-prescribing evidence base and stigmatizing language toward MOUD within counselors' responses, highlighting the potential to refine training materials for MOUD and mitigate stigmatizing beliefs.
Keywords: MOUD; Medications for opioid use disorder; opioid use disorder; stigma; substance use disorder counselors.
Conflict of interest statement
Declarations Competing interests. The authors declare that there is no conflict of interest.
Similar articles
-
Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.Am J Drug Alcohol Abuse. 2020 Nov 1;46(6):749-760. doi: 10.1080/00952990.2020.1807559. Epub 2020 Sep 24. Am J Drug Alcohol Abuse. 2020. PMID: 32969757
-
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17. J Subst Use Addict Treat. 2024. PMID: 38499248
-
Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.JAMA Netw Open. 2022 May 2;5(5):e2211363. doi: 10.1001/jamanetworkopen.2022.11363. JAMA Netw Open. 2022. PMID: 35536575 Free PMC article.
-
Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.Addict Sci Clin Pract. 2023 Jun 10;18(1):40. doi: 10.1186/s13722-023-00394-x. Addict Sci Clin Pract. 2023. PMID: 37301953 Free PMC article. Review.
-
The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.Addict Sci Clin Pract. 2021 Oct 11;16(1):62. doi: 10.1186/s13722-021-00266-2. Addict Sci Clin Pract. 2021. PMID: 34635170 Free PMC article. Review.
References
-
- Gordon AJ, Kenny M, Dungan M, Gustavson AM, Kelley AT, Jones AL, et al. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. Am J Addict. 2022;31(2):152–8. - PubMed
-
- Andrilla CHA, Patterson DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2022;38(1):87–92. - PubMed
-
- Darfler K, Sandoval J, Pearce Antonini V, Urada D. Preliminary results of the evaluation of the California Hub and Spoke Program. J Subst Abuse Treat. 2020;108:26–32. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials